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SuMMAry – The important goal in breast cancer treatment is to improve patient quality of life. 
Due to the huge economic burden, it is necessary to estimate the health state utility values for different 
breast cancer stages accurately. A group of 114 women filled out the euroqol-5D-3l questionnaire 
at two time points. The participants were divided into three groups, as follows: group 1 including 
healthy high-risk individuals; group 2 including patients with localized stage breast cancer; and group 
3 including patients with advanced stage breast cancer. results were expressed either as summary 
health state utility score or summary visual-analog score. The euroqol utility index score and euro-
qol visual-analog score were statistically significantly higher in the group of healthy high-risk indi-
viduals. The euroqol visual-analog score was mostly correlated with the anxiety/depression and pain/
discomfort quality of life dimensions. health state utility values for different breast cancer stages are a 
necessary tool to perform economic analyses in breast cancer management decision making, due to its 
huge economic burden. Special attention should be paid to assessment of the psychosocial aspects of 
the disease, as well as pain management.
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Introduction
breast cancer is among the most common cancers 
in women and the second leading cause of cancer-re-
lated death in women1. it is estimated that one in eight 
(12.3%) women will develop breast cancer during their 
lifetime. in 2012, 1,670,000 new cases of breast cancer 
were recorded worldwide. in europe, nearly 460,000 
women are affected every year2,3.
Despite available hormonal and targeted therapies, 
chemotherapy, improved surgical therapy and radio-
therapy of breast cancer, 30%-40% of patients still de-
velop metastatic disease. locally advanced breast can-
cer, metastatic breast cancer, inflammatory breast can-
cer or breast cancer where curative surgical treatment 
or radiotherapy is not possible are considered advanced 
breast cancer stages4.
Patients diagnosed with breast cancer at an ad-
vanced stage are faced with a double burden, i.e. cop-
ing with significant adverse physical symptoms and 
with awareness that advanced stage breast cancer is a 
treatable but at long-term incurable disease. The suc-
cess of the modern era of chemotherapy, targeted and 
hormonal breast cancer therapy has increased the 
number of patients with metastatic disease who re-
ceive several treatment modalities at the same time5. 
having in mind that none of the advanced breast can-
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cer treatment modalities leads to permanent cure, the 
two main treatment goals are to prolong survival and 
to improve patient quality of life6. Assessment of these 
categories is becoming more important than the tradi-
tional treatment outcome measures, such as progres-
sion-free survival and overall survival7.
quality of life has two main components, objective 
and subjective ones. Objective parameters such as per-
sonal income, health, education level and employment 
status are deficient indicators because they do not take 
into account the views and beliefs of the individual. 
Therefore, definition of the quality of life should take 
into account subjective parameters describing subjec-
tive reactions to different experiences8.
Cummins has described 7 domains of the subjec-
tive quality of life component, as follows: material 
well-being, health, productivity, intimacy, safety, place 
in society, and emotional well-being. he also explored 
the connection between the quality of life subjective 
and objective components and concludes that the cor-
relation is low and has a non-linear character9,10.
There are several definitions in the literature that 
attempt to define this subjective concept11. The world 
health Organization defines quality of life as the indi-
viduals’ perception of their position in life in the con-
text of the culture and value systems in which they live 
and in relation to their goals, expectations, standards 
and concerns12. gotay et al. define quality of life as a 
state of well being, which consists of a person’s ability 
to perform daily activities reflecting his/her physical, 
mental and social well-being and satisfaction with 
daily functioning and disease control13. Calman gives 
an interesting definition of the quality of life as a clash 
between the patient’s expectations and achievements. 
The smaller the clash, the better is quality of life14. 
health-related quality of life (hrqol) is a subjective 
assessment of health and welfare. it has been desig-
nated as a special term to emphasize the fact that this 
dimension is clearly distinguishable from other phe-
nomena that contribute to better quality of life, such as 
income, freedom, or the environment15.
Due to inconsistency of the quality of life defini-
tion, there are many available instruments that mea-
sure quality of life with two basic approaches, i.e. ge-
neric instruments are multidimensional ones, devel-
oped to assess the general quality of life and specific 
instruments that measure quality of life in certain dis-
eases. generic instruments are widely used, particu-
larly to determine demographic and cross-cultural dif-
ferences in the quality of life16.
A quite often utilized and validated instrument 
from the group of generic instruments is euroqol-5D 
(eq-5D), which is used to assess health status for the 
purpose of health-economic analysis. it has been de-
veloped by the euroqol group in 1987 and used in 
numerous clinical trials, observational studies and re-
search. eq-5D is a standardized measure of health 
status developed as a simple, generic measure of health 
status for use in clinical and economic analysis. As it 
can be administered to a large number of diseases and 
types of treatment, this form is a simple descriptive 
profile of health status expressed as a ‘utility index 
score’ at the time of completion of the questionnaire. 
Cognitively undemanding, it is designed so as not to 
be time-consuming but easily filled out by the subject 
alone17.
quality of life estimated by the eq-5D question-
naire is part of the quality Adjusted life years 
(qAly) metrics, a term that incorporates life expec-
tancy, as well as quality of life. it is used in health eco-
nomics to determine priorities in redistribution of re-
sources18.
The present study was conducted as part of the 
cost-effectiveness analysis of the implementation of 
hereditary cancer genetic counseling and testing pro-
gram for the first time in Croatia. The aim of the study 
was to compare the hrqol measured by eq-5D 
questionnaire and expressed as eq utility index score 
(eq uS) or eq visual-analog score (eq vAS) in lo-
calized and advanced stage breast cancer patients with 
healthy high-risk population. The second goal of the 
study was to investigate the dimensions of the ques-
tionnaire that mostly affect the quality of life expressed 
as vAS.
Subjects and Methods
The study was approved by the Central ethics 
Committee, School of Medicine, university of zagreb 
and ethics Committee, Sestre milosrdnice university 
hospital Centre, zagreb. Participants were informed 
verbally and in writing about the purpose and methods 
of the study prior to giving their informed consent for 
participation and publication of the results.
The study was conducted at the genetic Counseling 
unit, university hospital for tumors, Sestre milosrd-
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nice university hospital Centre from January 1, 2016 
until December 31, 2016. Participation in the study was 
offered to all women having presented for genetic coun-
seling during the mentioned period irrespective of age. 
The inclusion criteria were as follows: women diagnosed 
with breast cancer in any stage, and healthy women that 
were eligible for BRCA1/2 gene genetic testing accord-
ing to the recent national Comprehensive Cancer net-
work (nCCn) guidelines19. The questionnaire was of-
fered at first consultation (first time point) and 3 months 
later (second time point). The exclusion criteria were as 
follows: men with breast cancer; women diagnosed with 
cancer other than breast cancer; and participants that 
failed to fill out the questionnaire completely and at 
both time points.
Out of 135 participants that were offered to fill out 
the questionnaire, 114 women were included in the 
study according to the inclusion criteria. They were di-
vided into three groups: group 1 including healthy 
high-risk individuals; group 2 including patients with 
localized stage breast cancer; and group 3 including 
patients with advanced stage breast cancer. The group 
of high-risk subjects consisted of healthy women that 
were eligible for BRCA1/2 gene genetic testing ac-
cording to the recent nCCn guidelines. 
The participants filled out the questionnaire during 
their visit to the genetic Counseling unit at two time 
points, i.e. at the time of diagnosis of breast cancer in 
case of women diagnosed with breast cancer or at the 
time of first consultation in case of healthy women, 
and 3 months later.
Instrument
The first part of the questionnaire consists of 5 
questions (i.e. eq-5D descriptive system), each of 
them representing one of the 5 health state dimen-
sions: mobility, self-care, usual activities, pain/discom-
fort and anxiety/depression. each dimension has 3 
levels: no problems, some problems, extreme problems. 
A total of 243 possible health states are defined in this 
way and converted to eD-5D utility index score using 
the time trade-off (ttO) valuation technique, rang-
ing from -0.594 to 1.000. for translation of eq-5D-
3l scores into health utilities, we used the united 
Kingdom value set according to the euroqol group 
instructions. The health state described with negative 
utility index values is considered worse than death 
 itself.
The second part of the questionnaire consists of 
eq visual-analog scale (eq vAS). The eq vAS re-
cords the respondent’s self-rated health on a vertical, 
visual analog scale where the endpoints are labeled 
“best imaginable health state” and “worst imaginable 
health state”. This information is used as a quantitative 
measure (“best imaginable health state” ranged as 100 
and “worst imaginable health state” ranged as 0) of 
health outcome as judged by the individual respon-
dents. The participants filled out the questionnaire 
with the help of an experienced examiner.
Statistical analysis
final eq uS and eq vAS were calculated as mean 
of the values obtained in the first and second time point. 
Mean value, standard deviation, median with minimum 
and maximum values were calculated for the eq uS 
and eq vAS for each group of patients.
Comparison of the groups was made using non-
parametric Mann-whitney test. to evaluate which of 
the five health state dimensions was mostly correlated 
to hrqol expressed as eq vAS, we used linear re-
gression model employing the stepwise backwards re-
gression method. A p-value of 5% was set as statisti-
cally significant. Statistical analysis was performed 
with the statistical tool r (http://www.r-project.org/).
Results
The total number of participants that met the in-
clusion criteria was 114. The group of healthy high-
risk individuals (group 1) consisted of 33 women, the 
group of patients with localized stage breast cancer 
(group 2) of 49 women, and the group of patients with 
advanced stage breast cancer (group 3) of 32 women.
table 1 shows the eq uS and eq vAS measured 
in the first and second time point and overall eq uS 
and eq vAS expressed as mean, standard deviation, 
and median with minimum and maximum for each 
group of patients. The overall eq uS and eq vAS 
were highest in the group of healthy high-risk indi-
viduals (0.85) and lowest in the advanced stage breast 
cancer group (0.68). The eq uS was statistically sig-
nificantly different between group 1 and group 2 
(p=0.013) and between group 1 and group 3 (p=0.004). 
The eq uS was not statistically different between 
group 2 and group 3 (p=0.469).
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Difference in eq vAS between group 1 and group 
2 was at the border of statistical significance (p=0.055). 
The eq vAS was statistically significantly different 
between group 1 and group 3 (p=0.006). The eq vAS 
was not statistically different between group 2 and 
group 3 (p=0.212).
linear regression model using the stepwise back-
wards regression method was performed to evaluate 
which of the five health state dimensions mostly af-
fected eq vAS. The results were calculated separately 
for eq vAS in each time point. The results of multi-
variate analysis are shown in table 2. The odds ratio 
(Or) for eq vAS in the first time point was lowest 
for the anxiety/depression level 3 (Or 0.64, 95% Ci 
0.56-0.74). The eq vAS in the second time point was 
mostly correlated with the pain/discomfort level 3 
(Or 0.79, 95% Ci 0.69-0.91), followed by anxiety/de-
pression level 3 (Or 0.79, 95% Ci 0.71-0.89).
Discussion
results of our study provided the health state util-
ity values for localized and advanced breast cancer 
stages and compared them with the utility values of 
Table 2. Results of the linear regression model expressed  
as OR and 95% CI for different levels of health state 
dimensions that were significant and incorporated  
in the final model
VAS 1st time point OR 95% CI
Mobility level 2 0.86 0.80-0.93
Mobility level 3 0.89 0.57-1.37
Pain/discomfort level 2 0.91 0.86-0.97
Pain/discomfort level 3 0.88 0.65-1.20
Anxiety/depression level 2 0.88 0.83-0.93
Anxiety/depression level 3 0.64 0.56-0.74
VAS 2nd time point OR 95% CI
Mobility level 2 0.88 0.83-0.93
Mobility level 3 1.32 0.97-1.80
Pain/discomfort level 2 0.95 0.90-1.00
Pain/discomfort level 3 0.79 0.69-0.91
Anxiety/depression level 2 0.88 0.83-0.94
Anxiety/depression level 3 0.79 0.70-0.89
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healthy high-risk individuals. The health state utility 
values were expressed as the mean value at three 
months of diagnosis. The health state utility values 
were highest in the group of healthy individuals and 
decreased in breast cancer patients according to the 
breast cancer stage. The vAS as a subjective indicator 
of the ndividual’s health state was mostly influenced 
by the pain/discomfort and anxiety/depression score. 
it is impossible to reach the ideal health state utility 
value that accurately describes the health state in each 
breast cancer stage. Our approach was based on the 
fact that in the period of three months of the diagnosis 
patients usually experienced different psychological 
states (from disbelief to depression) and different 
treatment modalities (surgery, radiotherapy, chemo-
therapy) that could influence their quality of life20. The 
summary health state utility value was obtained as a 
cross-section value during this period. The cross-sec-
tion time approach allows measurements in a mo-
derate number of study participants and gives a more 
accurate health state utility value than single measure-
ment.
Comparing our results with the results from the 
study by folse et al., we can conclude that the overall 
quality of life differed significantly in the healthy high-
risk group (utility value 0.85) compared to healthy 
population (utility value 1.00). There is a possibility 
that this family burden puts an additional psychologi-
cal burden that ultimately results in poorer quality of 
life21. we assume that this additional psychological 
pressure could be facilitated by the genetic counseling 
process prior to genetic testing and afterwards, accord-
ing to the study by eijzenga et al.22.
in our study, the health state utility values of local-
ized and advanced breast cancer stage were similar to 
other reported studies23.
Our study additionally highlighted the importance 
of early psychological support and pain management 
during breast cancer treatment. taking into account 
great progress in the development of various breast 
cancer therapeutic options in recent years, the society 
as a whole is facing new challenges. During and after 
the initial treatment, patients with breast cancer are 
faced with serious psychosocial issues such as personal 
and professional social disruption, depression, distress/
anxiety problems, fertility and sexuality doubts24. we 
are witnessing a period in which there is an increased 
number of breast cancer survivors and these psychoso-
cial problems are even more pronounced in this group 
of patients. breast cancer survivors are a vulnerable 
group with sometimes limited life expectancy. younger 
breast cancer patients are prone to depressive disor-
ders, and depression by itself could be an underdiag-
nosed state in older cancer patients. This raises a ques-
tion of routine psychological assessment of breast can-
cer patients during treatment and afterwards. The idea 
of death and dying should be appropriately processed 
rather than avoided during the process of psychologi-
cal counseling and patients should be empowered to 
reorder their life priorities25. One of the top clinical 
research needs in breast cancer is to increase efforts in 
survivorship research including supportive care and 
quality of life. The results of quality of life assessments 
in breast cancer patients are rarely used to guide clini-
cal practice decisions26.
Assessing hrqol is an important part of qAly 
metrics that has been widely used in economic analy-
ses. qAly is a measure that is defined by the duration 
and quality of life that can be generated by health in-
terventions. it represents the product of life expectancy 
and the health state utility value. qAly puts weight 
on the time spent in a particular health state. it is far 
away from the ideal outcome measure, with a number 
of shortcomings of technical and methodological na-
ture. however, the use of qAly as an outcome mea-
sure that will guide the decision on redistribution of 
resources means that the choice between the two 
groups of patients that are competing for the same 
medical intervention is explicit, and that the groups 
are compared to the universal principle. in this way, 
the benefit that the health care system generates from 
new investments is transparent27.
The breast cancer economic burden is evident from 
the fact that treatment expenses will reach $157 billion 
annually by 2020, with an overall 27% increase in 
medical costs in the united States. The costs are high-
est for patients in the advanced stage. having in mind 
this huge economic burden of breast cancer treatment 
and the need for economic analyses in the field, it is 
clear that it is necessary to estimate the health state 
utility values for different breast cancer stages as ac-
curately as possible20,28. Additional studies are needed 
to explore the hrqol in different breast cancer stag-
es with special attention to psychological and pain 
 issues.
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Conclusion
in conclusion, we can say that the health state util-
ity values for different breast cancer stages are a neces-
sary tool for performing economic analyses in breast 
cancer management decision making, due to its huge 
economic burden. Our paper for the first time brings 
the health state utility values expressed as time cross-
section values for localized and advanced breast cancer 
stages, as well as for healthy high-risk population.
The results of our study showed the importance of 
anxiety/depression and pain/discomfort dimensions in 
the overall quality of life of breast cancer patients. 
quality of life is an important treatment outcome and 
special attention has to be paid to the psychological 
burden of the disease, as well as to pain management.
Our study emphasized the importance of early 
psychological counseling in breast cancer patients and 
its implementation at the national level. The study was 
conducted as part of a cost-effectiveness analysis of the 
implementation of genetic counseling and testing pro-
gram for hereditary breast cancer in Croatia. The re-
sults from this study will be used in further economic 
analysis.
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Sažetak
DefinirAnJe KvAlitete ŽivOtA  
KOD bOleSniCA S lOKAlizirAniM i uznAPreDOvAliM StADiJeM rAKA DOJKe  
– Prvi KOrAK PreMA OnKOlOŠKOM genetSKOM SAvJetOvAnJu
T. Žigman, I. Lukša, G. Mihaljević, M. Žarković, I. Kirac, D. V. Vrdoljak i Lj. Šerman
važan cilj u liječenju raka dojke je poboljšanje kvalitete života bolesnica. zbog velikog financijskog opterećenja važno je 
točno procijeniti parametre kvalitete života (engl. health state utility values) za različite stadije raka dojke. Skupina od 114 
žena ispunila je upitnik euroqol-5D-3l u dvije vremenske točke. Sudionice su podijeljene u 3 skupine: 1. skupina – zdrave 
visokorizične osobe; 2. skupina – bolesnice s lokaliziranim stadijem raka dojke i 3. skupina – bolesnice u uznapredovalom 
stadiju raka dojke. rezultati su predočeni ili kao sveukupni indeks kvalitete života bolesnica (engl. summary health state utility 
score) ili kao rezultat na vizualno-analognoj ljestvici (engl. summary visual-analog score). EuroQol utility index score i EuroQol 
visual-analog score bili su statistički značajno viši u skupini zdravih visokorizičnih osoba. utvrđeno je da EuroQol visual-ana-
log score korelira sa sljedećim dimenzijama kvalitete života: anksioznost/depresija i bol/nelagoda. Parametri kvalitete života 
(engl. health state utility values) za različite stadije raka dojke važan su alat za provođenje ekonomske analize pri donošenju 
odluka o liječenju raka dojke, prvenstveno zbog velikog financijskog opterećenja. Osobitu pozornost trebalo bi usmjeriti na 
procjenu psihosocijalnih aspekata bolesti, kao i liječenju boli.
Ključne riječi: Rak dojke; Genetsko savjetovanje; Kvaliteta života; Analiza troškova i koristi
